Zura Bio Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZURA research report →
Companyzurabio.com
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
- CEO
- Sandeep C. Kulkarni
- IPO
- 2023
- Employees
- 30
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $267.24M
- P/E
- -6.14
- P/S
- 0.00
- P/B
- 2.14
- EV/EBITDA
- -0.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -54.60%
- ROIC
- -37.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-68,650,000 · -31.00%
- EPS
- $-1.06 · -76.67%
- Op Income
- $-75,246,000
- FCF YoY
- -130.64%
Performance & Tape
- 52W High
- $7.44
- 52W Low
- $0.98
- 50D MA
- $5.53
- 200D MA
- $4.41
- Beta
- 0.09
- Avg Volume
- 642.95K
Get TickerSpark's AI analysis on ZURA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Whale Gary | other | 263,000 |
| Apr 1, 26 | Nistala Kiran | other | 340,900 |
| Apr 1, 26 | Hyllengren Eric J | other | 340,900 |
| Apr 1, 26 | Davis Kim | other | 425,700 |
| Apr 1, 26 | Kulkarni Sandeep Chidambar | other | 894,000 |
| Feb 21, 26 | Nirula Ajay | other | 37,812 |
| Feb 21, 26 | Nirula Ajay | other | 0 |
| Feb 26, 26 | AI Biotechnology LLC | buy | 2,000,000 |
| Feb 21, 26 | Eisner Mark | other | 37,812 |
| Feb 21, 26 | Eisner Mark | other | 0 |
Our ZURA Coverage
We haven't published any research on ZURA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZURA Report →